Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: Future Oncol. 2011 Dec;7(12):1415–1428. doi: 10.2217/fon.11.124

Table 4.

Combination of histone deacetylase inhibitors with other antitumor agents in gynecologic cancers.

HDACi Class Other agents Disease Function Ref.
TSA Hydroxamic 5-aza-2′-
deoxycytidine
Endometrial cancer Inhibit VEGF receptors VEGFR1, VEGFR2 and Nrp1-1.85
Downregulate DNMT3B mRNA and protein expression
[31,62,108]
PXD101
(belinostat)
Hydroxamic Carboplatin
Paclitaxel
Ovarian, epithelial
and fallopian
tube cancers
Histone H4 hyperacetylation [12,104]
TSA, NaB Paclitaxel Ovarian cancer Induction of p53 protein [89]
TSA Hydroxamic Paclitaxel Endometrial cancer Induction of p21
Increase acetylation of tubulin and microtubule
stabilization
[41]
SAHA
(vorinostat),
NaB
Hydroxamic,
short-chain
fatty acids
Aspirin Ovarian cancer Induction of apoptosis [97]
PXD101
(belinostat)
Hydroxamic Docetaxel
Paclitaxel
Carboplatin
Ovarian cancer Enhance carboplatin anticancer effect in xenograft
Increase the phosphorylation of H2AX induced
by carboplatin
Enhance induction of histone H4 hyperacetylation
[83]
SAHA Hydroxamic Paclitaxel Ovarian cancer Slightly induce apoptosis [103

HDACi: Histone deacetylase inhibitor; SAHA: Suberoylanilide hydroxamic acid; TSA: Trichostatin.